Evolution of iCAR-T Platform and Future of Alloy Therapeutics



1	2	3	4	5
Professor Shinya Yamanaka generated induced pluripotent stem cell (iPSC) lines. iPSC received significant excitement as every type of human cell could potentially be created, greatly expanding the potential for regenerative medicine, such as replacing diseased and failed organs.	Takeda and CiRA launch a decade-long Joint Research Program (T-CiRA) to advance iPSC science into therapeutics. As part of T-CiRA program, Shin Kaneko's team advances lymphoid differentiation process to achieve central memory-like T-cells and obtain proof of concept as cancer therapy in animal models	iPSC-derived CAR-T (iCAR-T) Platform is transferred to Takeda for further development.	Alloy and Takeda enter into collaboration and license agreement, enabling Alloy to develop therapeutics through collaboration with Pharma, Biotech, and NewCo's. Takeda maintains access to the platform for potential future development.	Going forward, Alloy will offer partners a fully integrated drug discovery and development platform with iCAR-T cell therapies which includes: Best-in-Class Science Mature CMC Process

Alloy Therapeutics